To support this increase in parenteral manufacturing capacity, Althea has invested in additional operational capabilities, more visual inspection suites, automated quality systems, and project management expansion. The expansion also accomodates its microbial and plasmid DNA capabilities, crystallization formulation technology (Crystalomics) programs, and its recent entry into the highly potent API and ADC bioconjugation and fill and finish services.
Chris Duffy, senior vice president of operations, said, “We are very pleased and eager to provide this additional fill and finish capacity to all of our clients. We recognize and appreciate the need for shorter lead times and flexible timelines, which are critical to developers of biologics-based drug products. The addition of this second manufacturing shift will allow us to further accommodate the substantial increase in demand we’ve observed from our clinical and commercial partners.”